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The future of antivenoms – synthetic antitoxins
Antivenoms are still being produced by animal immunization protocols and are therefore 
associated with high immunogenicity for human recipients [1].  Here we report the first step 
towards discovery of synthetic antitoxins that could be used for development of a fully synthetic 
antivenom against neurotoxin from cobras (Naja genus).
Cross-reactive peptides for pan-specific antivenom
Given that other elapid venoms are rich in α-neurotoxins [3,4], the identified inhibitor may 
potentially provide protection against the neurotoxic effects exerted by α-neurotoxins present in a 
broad range of venoms.
Figure 3: ELISA tests of panning rounds and selected monoclonal phage colonies. Phage display 
screening coupled to both normal sequencing of hits and next generation sequencing of panning 
rounds lead to the discovery of 3 peptides that interact with α-cobratoxin.
Figure 5: Schematic overview of physiological mechanism. A: α-cobratoxin inhibits the nicotinic 
acetylcholine receptor (nAChR) at the endplate of muscle fibers leading to flaccid paralysis. B: 
Peptides P1 and P3 bind to α-cobratoxin and prevent the toxin from inhibiting the nAChR. C: 
Measured ion currents through the nAChR in Xenopus laevis oocyte two electrode voltage clamp 
(TEVC) assay showing that peptides P1 and P3 prevent inhibition of ion current flow.
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Figure 2: The high lethality of Naja kaouthia (Monocled cobra) venom is due to the high amount of 
α-neurotoxins, with the most abundant and toxic component being α-cobratoxin [2]. Kd was 
determined by Isothermal Calorimetry (ITC). Illustration of binding (binding place unknown).
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Figure 4: Peptides prevent α-cobratoxin from inhibiting nicotinic acetylcholine receptors in Xeno-
pus laevis oocytes in two electrode voltage clamp (TEVC) experiments. 100 µM acetylcholine-
gated currents were recorded alone (control, “C”); in the continued presence of either 40 nM α-
cobratoxin alone (light blue bars, “1-3”) or 40 nM α-cobratoxin and 100 µM peptide (dark blue 
bars, “1-3”); and then alone again (wash, “w1-w3”). P1 and P3 prevent the inhibition caused by 
α-cobratoxin, whereas P2 enhances both the onset and wash-out of inhibition.
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Figure 1: Naja kaouthia by S. Ganguly 2012
